goetzpartners securities advised on Marinomed Biotech's Initial Public Offering of EUR 22.4 million (gross proceeds amount to EUR 19.5 million excl. over-allotments/greenshoe)

Deal Announcement

Marinomed Biotech AG announced on 30 January 2019 that a total amount of 299,000 new bearer shares were placed with investors at the offer price of EUR 75 per share, consisting of 260,000 shares from the base offer and 39,000 shares due to over-allotments. Assuming full exercise of the greenshoe option, gross proceeds will amount to EUR 22.4 million. The proceeds from the IPO shall be used primarily to fund the pivotal Phase III study of Budesolv, Phase II and Phase III studies of Tacrosolv as well as the extension of the Carragelose® OTC platform.

Based on the total number of 1,299,000 shares (assuming a full exercise of the greenshoe option) and the Offer Price of EUR 75 per share, the market capitalization of Marinomed amounts to approximately EUR 97.4 million. The free float is around 31% (thereof around 22% by from new investors in the IPO). In case all convertible bonds are converted to new shares of Marinomed Biotech AG, the free float increases to 39%.

From 1 February 2019, the Marinomed shares started trading under the symbol "MARI" on the official market (prime market segment) of the Vienna Stock Exchange. The Marinomed Management Board has committed itself to a lock-up period of 36 months, almost all of the other existing shareholders and the company itself to a lock-up period of 12 months.

goetzpartners securities Limited acted as Co-Lead Manager in Marinomed's Initial Public Offering.

 

ABOUT MARINOMED BIOTECH AG

Marinomed Biotech AG is a Vienna based biopharmaceutical company focusing on the development of innovative products derived from patent protected technology platforms to treat respiratory and ophthalmic conditions. The Carragelose® platform comprises innovative patent protected products targeting viral infections of the respiratory tract. Carragelose® is used in nasal sprays, throat sprays and lozenges, which are sold in more than 30 countries around the world in collaboration with international partners. The Marinosolv® technology platform increases the efficacy of hardly soluble compounds for the treatment of sensitive tissues such as the eyes and nose. 

Marinomed Biotech AG announced on 30 January 2019 that a total amount of 299,000 new bearer shares were placed with investors at the offer price of EUR 75 per share, consisting of 260,000 shares from the base offer and 39,000 shares due to over-allotments. Assuming full exercise of the greenshoe option, gross proceeds will amount to EUR 22.4 million. The proceeds from the IPO shall be used primarily to fund the pivotal Phase III study of Budesolv, Phase II and Phase III studies of Tacrosolv as well as the extension of the Carragelose® OTC platform.

Based on the total number of 1,299,000 shares (assuming a full exercise of the greenshoe option) and the Offer Price of EUR 75 per share, the market capitalization of Marinomed amounts to approximately EUR 97.4 million. The free float is around 31% (thereof around 22% by from new investors in the IPO). In case all convertible bonds are converted to new shares of Marinomed Biotech AG, the free float increases to 39%.

From 1 February 2019, the Marinomed shares started trading under the symbol "MARI" on the official market (prime market segment) of the Vienna Stock Exchange. The Marinomed Management Board has committed itself to a lock-up period of 36 months, almost all of the other existing shareholders and the company itself to a lock-up period of 12 months.

goetzpartners securities Limited acted as Co-Lead Manager in Marinomed's Initial Public Offering.

 

ABOUT MARINOMED BIOTECH AG

Marinomed Biotech AG is a Vienna based biopharmaceutical company focusing on the development of innovative products derived from patent protected technology platforms to treat respiratory and ophthalmic conditions. The Carragelose® platform comprises innovative patent protected products targeting viral infections of the respiratory tract. Carragelose® is used in nasal sprays, throat sprays and lozenges, which are sold in more than 30 countries around the world in collaboration with international partners. The Marinosolv® technology platform increases the efficacy of hardly soluble compounds for the treatment of sensitive tissues such as the eyes and nose.

 

TRANSACTION TEAM

Martin Brunninger
Managing Director
Email

Ulrich Kinzel
Managing Director

Wolf Dornbusch
Director

Youchen Xing
Associate

Erland Sternby
Marketing Sales